Pricing Log in Create free account

Fate Therapeutics, Inc. (FATE) vs Korro Bio, Inc. (KRRO)

Fate Therapeutics, Inc. and Korro Bio, Inc. are both Biotechnology companies. Fate Therapeutics, Inc. is the larger, with a market value of $223.1M against $202.5M — 1.1× the size. Fate Therapeutics, Inc. grew revenue faster over the last twelve months: −23.4% against −81.9%. Korro Bio, Inc. has the higher net margin (0.00% vs −1,941.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Fate Therapeutics, Inc. leads on 8 and Korro Bio, Inc. on 6.

Valuation

Metric FATE KRRO Biotechnology median
P/E n/m n/m 10.60
P/S 34.13 40.65 9.40
P/B 1.44 2.52 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 14.04 25.53 9.02
Earnings yield (57.07%) (67.80%) (32.88%)
Free cash flow yield (47.59%) (26.27%) (23.13%)

Profitability

Metric FATE KRRO Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (2,058.08%) 0.00% 0.00%
Net margin (1,941.09%) 0.00% 0.00%
Free cash flow margin (1,624.06%) 0.00% 0.00%
Return on equity (60.75%) (97.69%) (51.96%)
Return on assets (39.89%) (62.03%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric FATE KRRO Biotechnology median
Revenue growth (TTM) (23.36%) (81.87%) 6.76%
EPS growth (last fiscal year) 29.88% (33.19%) 29.88%
Revenue growth, 5-year CAGR (26.71%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FATE KRRO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.85 9.55 4.97
Net debt to EBITDA 1.47 0.64 1.01

Dividend

Metric FATE KRRO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric FATE KRRO Biotechnology median
Market cap 223.08m 202.45m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack